Hyperglycemia and reduced adiposity of streptozotocin-induced diabetic mice are not alleviated by oral benzylamine supplementation

This is the authors' abstract. We don't add key points for this paper.

BACKGROUNDBenzylamine (Bza) oral administration delays the onset of hyperglycemia in insulin-resistant db -/-mice; a genetic model of obesity and type 2 diabetes. AIMTo extend the antihyperglycemic properties of oral benzylamine to a model of insulin-deficient type 1 diabetes. METHODSMale Swiss mice were rendered diabetic by streptozotocin treatment (STZ) and divided in two groups: one received 0.5% Bza as drinking solution for 24 d (STZ Bza-drinking) while the other was drinking water ad libitum.Similar groups were constituted in age-matched, nondiabetic mice.Food intake, liquid intake, body weight gain and nonfasting blood glucose levels were followed during treatment.At the end of treatment, fasted glycemia, liver and white adipose tissue (WAT) mass were measured, while glucose uptake assays were performed in adipocytes. RESULTSSTZ diabetic mice presented typical features of insulin-deficient diabetes: reduced body mass and increased blood glucose levels.These altered parameters were not normalized in the Bza-drinking group in spite of restored food and water intake.Carpéné C et al.Benzylamine and glucose handling in lipoatrophic diabetic mice WJD https://www.wjgnet.com753